US EditionNovo Halves Ozempic Price to $499 a Month for Those Paying Cash
Novo Nordisk and GoodRx cut Ozempic and Wegovy prices to $499 monthly, halving costs to improve access for uninsured and underinsured patients in the U.S.
- Novo Nordisk is offering cash-paying US patients its diabetes treatment Ozempic for $499 per month, less than half its list price, amid pressure to lower drug costs.
- Patients can access the discounted price through Novo Nordisk's website, assistance program, and online pharmacy, as well as through GoodRx at over 70,000 pharmacies nationwide.
- The move aims to expand access to Ozempic for uninsured patients and steer them away from potentially unsafe alternatives, according to Novo Nordisk executive Dave Moore.
108 Articles
108 Articles
Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash
Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, customers will be able to buy a month’s supply of Novo Nordisk’s semaglutide pen products for $499 through GoodRx. The list price for…
Americans with diabetes and insufficient health insurance or those trying to lose weight will be relieved. They will now get the drug Ozempic for half the price if they pay for it out of their own pocket. It will remain at the same price level regardless of the insurance company. According to local media, this is the result of political pressure to reduce drug prices in the country.
Coverage Details
Bias Distribution
- 64% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
